Highly dispersible powders, compositions and methods for preparation
A method for the selection of pharmaceutically acceptable excipients that allow for the production of highly dispersible powders produced by spray drying.
1. A pharmaceutically acceptable dispersible powder, comprising gallium and a hydrophobic monomeric amino acid excipient that is more hydrophobic than alanine, according to the Kyte-Doolittle index, wherein the powder only contains amino acids in monomeric form,
wherein the mass of the excipient is 15%-25% of the mass of the powder, and
wherein the fine particle distribution (FPD) of the powder that is under 3.3 microns is greater than 30%, or wherein the mass median aerodynamic diameter (MMAD) of the powder is under 10 microns.
2. The pharmaceutically acceptable dispersible powder of claim 1 , wherein the mass of the excipient is at least 20.5% the mass of the powder and 22% or less than the mass of the powder.
3. The pharmaceutically acceptable dispersible powder of claim 1 , wherein the mass of the excipient is about 21% of the mass of the powder.
4. The pharmaceutically acceptable dispersible powder of claim 1 , wherein the gallium is formulated as gallium citrate or gallium nitrate.
5. The pharmaceutically acceptable dispersible powder of claim 1 , wherein the amino acid is leucine.
6. The pharmaceutically acceptable dispersible powder of claim 1 , wherein the amino acid is selected from the group consisting of isoleucine, valine, phenylalanine, cysteine, and methionine.
7. The pharmaceutically acceptable dispersible powder of claim 1 , made by a method comprising spray freeze-drying, fluidized bed drying, supercritical fluid assisted drying, or spray coating.
8. A pharmaceutically acceptable dispersible powder comprising a monomeric amino acid hydrophobic excipient, other than leucine, that is more hydrophobic than alanine, according to the Kyte-Doolittle index, wherein the powder only contains amino acids in monomeric form,
wherein the mass of the excipient is 15%-25% of the mass of the powder, and wherein the fine particle distribution (FPD) of the powder that is under 3.3 microns is greater than 30%, or wherein the mass median aerodynamic diameter (MMAD) of the powder is under 10 microns.
9. The pharmaceutically acceptable dispersible powder of claim 8 , further comprising a pharmaceutically-active molecule.
10. The pharmaceutically acceptable dispersible powder of claim 9 , wherein the pharmaceutically-active compound is gallium.
11. The pharmaceutically acceptable dispersible powder of claim 9 , wherein the pharmaceutically-active compound is gallium citrate or gallium nitrate.
12. The pharmaceutically acceptable dispersible powder of claim 8 , wherein the mass of the excipient is at least 20.5% the mass of the powder and 22% or less than the mass of the powder.
13. The pharmaceutically acceptable dispersible powder of claim 8 , wherein the mass of the excipient is about 21% of the mass of the powder.
14. The pharmaceutically acceptable dispersible powder of claim 8 , wherein the amino acid is selected from the group consisting of isoleucine, valine, phenylalanine, cysteine, and methionine.
15. The pharmaceutically acceptable dispersible powder of claim 8 , made by a method comprising spray freeze-drying, fluidized bed drying, supercritical fluid assisted drying, or spray coating.
16. A pharmaceutically acceptable dispersible powder comprising monomeric leucine, wherein the mass of the leucine is at least 20.5% the mass of the powder and 22% or less than the mass of the powder, wherein the powder only contains amino acids in a monomeric form, and
wherein the fine particle distribution (FPD) of the powder that is under 3.3 microns is greater than 30%, or wherein the mass median aerodynamic diameter (MMAD) of the powder is under 10 microns.